NanoPhoria Bioscience secures €83.5 Million Series A to Advance Breakthrough Heart Failure Therapy and Expand Portfolio for Novel Nano-in-Micro Delivery Platform




NanoPhoria Bioscience secures €83.5 Million Series A to Advance Breakthrough Heart Failure Therapy and Expand Portfolio for Novel Nano-in-Micro Delivery Platform

• Series A financing will advance the company’s lead candidate for heart failure with reduced ejection fraction (HFrEF) through completion of early clinical development and GMP manufacturing scale-up and regulatory programs
• Funds raised will also enable NanoPhoria to pursue indications beyond HFrEF
• The raise is the largest ever Italian biotech, Series A round

MILAN–(BUSINESS WIRE)–NanoPhoria Bioscience, a Milan-based biotech company, today announced the successful first close of its €83.5 million Series A financing round. The round was led by XGEN Venture, Sofinnova Partners, and CDP Venture Capital, with Panakès Partners also investing and one other undisclosed investor joining the round.

The funding will propel NanoPhoria’s lead candidate, NP-MP1, through IND-enabling studies and early clinical development. NP-MP1 is a first-in-class peptide that targets cardiac L-type calcium channels to improve ejection fraction for the treatment of heart failure with reduced ejection fraction (HFrEF).

Delivered via NanoPhoria’s proprietary lung-to-heart nano-in-micro technology, NP-MP1 has demonstrated excellent efficacy in preclinical models of heart failure and aims to address a root cause of HFrEF by improving cardiac contractility. HFrEF is a condition affecting millions globally with a five-year mortality rate of approximately 40%.

“This financing is a transformational milestone for NanoPhoria,” said Claudio De Luca, CEO and co-founder. “It enables us to accelerate clinical development of NP-MP1 and expand our pipeline. Our innovative delivery platform allows us to target previously inaccessible cellular targets in the cardiomyocyte, thereby bringing us closer to delivering life-changing treatments for patients living with serious cardiac and other chronic conditions who are underserved by existing treatments. We are profoundly grateful to our scientific founders, our investors, our Board, and our Chair, Suman Shirodkar, whose vision and efforts have shaped NanoPhoria’s progress and ambition.”

This investment perfectly aligns with XGEN’s strategy to lead early financing rounds in the most innovative Italian startups that address true medical needs,” said Paolo Fundarò, Managing Partner at XGEN Venture. “NanoPhoria’s science provides a novel, and viable, way of delivering highly potent therapeutics directly to the heart and we look forward to working alongside such a fantastic syndicate of investors.”

“NanoPhoria’s platform has the potential to redefine treatment paradigms in cardiovascular and other chronic diseases which is why we are excited to invest in this company,” added Henrijette Richter, Managing Partner at Sofinnova Partners. “This financing builds on the early support of my colleague Lucia Faccio, Partner in the Sofinnova Telethon Strategy, whose role was instrumental in supporting the company in its early days to take shape. The investment reflects Sofinnova’s broader commitment to backing world-class science across Europe, from early-stage company creation to late-stage growth.”

About NanoPhoria

Founded in 2022 by Daniele Catalucci, Michele Iafisco, Alessio Alogna and Claudio De Luca NanoPhoria is a spin-off from Italy’s National Research Council (CNR). The company is developing a versatile, nano-in-micro & lung-to-heart delivery platform based on inorganic calcium phosphate nanoparticles. The company’s first product is a pre-clinical stage treatment for heart failure with reduced ejection fraction (HFrEF), a chronic syndrome affecting the lives of millions worldwide. NanoPhoria is supported by Sofinnova Partners, XGEN Venture, CDP Venture Capital and other investors. Learn more at NanoPhoria.com

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.

Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over €4 billion in assets. For more information, please visit: sofinnovapartners.com.

About XGEN Venture

XGEN Venture is a premier venture capital firm dedicated to advancing innovations in the life sciences sector. With nearly two decades of experience, the founding team has a proven track record of building breakthrough life sciences startups in Italy and internationally. XGEN is currently investing out of its first fund, XGEN Venture Life Science Fund, launched in 2022, and focusing on early-stage investments across biotechnology, medical devices, and diagnostics. For more information: www.xgenventure.com

About CDP Venture Capital

CDP Venture Capital is an Asset Management Company with €4.7 billion in assets under management. It operates with a series of funds that aim to support startups throughout all their life stages, making both direct and indirect investments. The CDP Venture Capital contribution to Nanophoria’s Series A round was performed through its Large Ventures Fund.

About Panakès Partners

Panakès Partners is a Venture Capital firm, based in Milan, that invests in the most ambitious companies and teams developing revolutionary technologies and products in the field of life sciences with the aim of improving the lives of people around the world. Panakès, founded in 2016 by Fabrizio Landi, Alessio Beverina and Diana Saraceni, has €250 million under management. www.panakes.it

Contacts

Barnaby Pickering, Director, 59 North Communications

Barnaby.Pickering@59North.bio
+447300796779

Claudio De Luca, CEO and Founder, NanoPhoria

claudio.deluca@nanophoria.com

Ignota Labs Acquires Kronos’s Clinical Pipeline




Ignota Labs Acquires Kronos’s Clinical Pipeline

Kronos, once valued at $3.5B, Had Two Phase 2 Stage Assets

CAMBRIDGE, England–(BUSINESS WIRE)–Ignota Labs, the AI drug turnaround company, has announced its acquisition of Kronos’s clinical assets, istisociclib, a CDK9 inhibitor, and entospletinib and lanraplenib, SYK inhibitors. Kronos’ valuation peaked at $3.5 billion after its IPO; however, it failed to progress its assets past Phase 2 trials and subsequently ceased operations. Given the challenges relating to safety and clinical positioning, Ignota Labs saw promise in the clinical portfolio and has acquired Kronos’s clinical IP in full.

Ignota Labs combines cheminformatics and bioinformatics in its AI platform, SAFEPATH, to identify the root causes of safety issues and improve safety while maintaining therapeutic effectiveness. Ignota’s proprietary process will now assess the Kronos assets to identify the issue, solve the causes of toxicity, and develop the drug clinically and commercially to get it to patients.

Sam Windsor, Co-Founder and CEO at Ignota Labs, said: “We are acquiring assets that have demonstrated therapeutic effect, but failed in their development and were shelved despite tens of millions of dollars already invested in them. This is where Ignota Labs come in: unlocking value by turning around failing drugs so that they can quickly get back into clinical trials and bring fresh hope to the patients waiting for these drugs.”

Blood cancers and autoimmune disorders remain large, underserved markets. Chronic lymphocytic leukaemia (CLL) is an $8 billion market globally, and immune thrombocytopenia purpura (ITP) represents a $1.5 billion opportunity. By reviving these clinical assets, Ignota Labs is uniquely positioned to address these substantial patient and market needs.

Dr. Jordan Lane, Co-Founder and Chief Scientific Officer, said: “These drugs are desperately needed. Both CKD9 inhibitors and SYK inhibitors have shown clinical benefit to patients. By in-licensing these drugs, we are uniquely placed to bring these best-in-class drugs to patients with diseases that desperately need them.”

About Ignota Labs

Ignota Labs turns around promising but failing drugs, bringing new life to abandoned projects and new hope to patients. In preclinical and clinical studies, safety assessments typically reveal what went wrong—such as liver damage or heart issues—but fail to explain why these issues occurred, or how they might be mitigated. SAFEPATH is a first-of-its-kind AI platform that combines advanced machine learning models with a multimodal data approach to enable a deep understanding of toxicity mechanisms, and offers actionable insights to facilitate drug turnaround. The clinical stage company was founded by Cambridge researchers and pharmaceutical consultants, and investors include AIX Ventures, Montage Ventures, and Modi Ventures.

For more information, visit www.ignotalabs.ai.

Contacts

Media contact: hailey@commplicated.com / +44 07480 559199

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia




Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

– ALTO-101, a novel PDE4 inhibitor, has demonstrated pro-cognitive effects in healthy volunteers –

– Designation highlights the significant unmet need for new treatments for cognitive impairment associated with schizophrenia (CIAS) –

– Enrollment remains ongoing in a Phase 2 proof-of-concept study of ALTO-101 in patients with CIAS –

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–$ANRO #FastTrack–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS). There are currently no approved treatments for CIAS, a core feature of schizophrenia that severely impacts daily functioning and quality of life for millions of patients.

Fast Track designation is an FDA process designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. A drug that receives Fast Track designation may be eligible for more frequent meetings with the FDA to discuss the drug’s development plan, as well as eligibility for accelerated approval and priority review, if relevant criteria are met.

“Receiving Fast Track designation from the FDA underscores the critical need for new, effective treatments for patients suffering from cognitive impairment associated with schizophrenia,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. “This designation is a significant milestone for the ALTO-101 program and we believe it is a testament to its potential as a novel treatment approach. Our Phase 1 data, which demonstrated significant and clinically relevant effects of ALTO-101 on both EEG measures and cognitive performance in healthy subjects, provides strong validation for its mechanism. We are committed to advancing this program expeditiously for the millions of patients who currently have no approved treatment options to address these debilitating cognitive deficits.”

ALTO-101 is a novel small molecule phosphodiesterase-4 (PDE4) inhibitor. The PDE4 enzyme plays a key role in the brain by breaking down cyclic adenosine monophosphate (cAMP), a molecule crucial for neuronal signaling and synaptic plasticity, which are fundamental to learning and memory. By inhibiting PDE4, ALTO-101 increases cAMP levels, which is believed to enhance neural circuits and improve cognitive function. The cognitive deficits in schizophrenia, which include impaired attention, memory, and executive function, represent a substantial and underserved aspect of the illness.

About Cognitive Impairment Associated with Schizophrenia (CIAS)

Cognitive impairment is a core and disabling feature of schizophrenia, affecting areas such as memory, attention, processing speed, and executive function. These deficits are a primary determinant of poor functional outcomes for patients, impacting their ability to work, maintain social relationships, and live independently. Currently, there are no approved treatments for CIAS, representing a significant unmet medical need for the millions of people living with schizophrenia worldwide.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

Forward-Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “expects,” “plans,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Alto’s expectations about the potential benefits, activity, effectiveness and safety of its product candidates and Precision Psychiatry Platform (“Platform”); statements regarding Alto’s expectations for the design, progress and results of its ongoing Phase 2 POC trial of ALTO-101 in CIAS; Alto’s ability to recognize the benefits of receiving Fast Track designation, Alto’s expectations with regard to the design and results of its clinical trials. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including uncertainties inherent in the initiation, progress and completion of clinical trials, including the Phase 2 POC trial of ALTO-101, and other important factors, any of which could cause Alto’s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section titled “Risk Factors” in each of Alto’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and Alto’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Alto may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law.

Availability of Information on Alto’s Website

Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.

Contacts

Investor and Media Contact:
Nick Smith

investors@altoneuroscience.com
media@altoneuroscience.com

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)




KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FRAMINGHAM, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 30,000 shares of KalVista common stock on October 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the first day a closing price is reported following the grant date.

One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.

The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

About KalVista Pharmaceuticals, Inc.

KalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered and developed EKTERLY^®—the first and only oral on-demand treatment for hereditary angioedema (HAE)—and continues to work closely with the global HAE community to improve treatment and care for this disease around the world. For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn, X, Facebook and Instagram.

Contacts

Ryan Baker

Head, Investor Relations

(617) 771-5001

ryan.baker@kalvista.com

Molly Cameron

Director, Corporate Communications

(857) 356-0164

molly.cameron@kalvista.com

Bruker Announces Orders for NIH- and NSF-Funded NMR Systems from New York Structural Biology Center, University of Delaware and Northwestern University




Bruker Announces Orders for NIH- and NSF-Funded NMR Systems from New York Structural Biology Center, University of Delaware and Northwestern University

BILLERICA, Mass.–(BUSINESS WIRE)–$BRKR #BRKR—Bruker Corporation (Nasdaq: BRKR) today announced new orders for advanced Nuclear Magnetic Resonance (NMR) instrumentation from the New York Structural Biology Center (NYSBC), the University of Delaware and Northwestern University. Supported by the National Institutes of Health (NIH) and the National Science Foundation (NSF), these high-performance systems will enable leading research teams to pursue breakthroughs across a wide range of scientific research, drug discovery and disease biology disciplines.

The New York Structural Biology Center (NYSBC) ordered an NIH-funded Multifield NMR Relaxometry System. This advanced relaxometry system will be the first in North America and serves a consortium of nine research institutions in New York State as well as the national community through the NIH-funded Center on Macromolecular Dynamics by NMR spectroscopy. The system consists of a fast NMR sample shuttle system, a magnetic tunnel, and an electromagnetic field cycling coil (FCC), all mounted on a 700 MHz superconducting NMR magnet.

“This novel NMR Relaxometry system is a technological breakthrough that enables for the very first time measurements of spin-lattice relaxation rate constants for ¹H, ¹⁵N, ¹³C and other spins in biological macromolecules, including proteins and nucleic acids, over the range of magnetic fields from 100 µT to 16.4 T,” said Arthur G. Palmer, Professor of Biochemistry and Molecular Biophysics at Columbia University and Director of NMR Spectroscopy at NYSBC. “Critically, this instrumentation opens new time regimes for elucidating dynamics of these molecules and enables research ranging from understanding fundamental biological processes in normal and pathological states to discovery of potential new drugs for treatment of cancer and other diseases”.

At the University of Delaware, the Department of Chemistry and Biochemistry has ordered a 600 MHz Dynamic Nuclear Polarization (DNP) NMR spectrometer, funded by the NSF Major Research Instrumentation (MRI) program. This instrument will serve over 25 research groups at the University of Delaware and 12 collaborating institutions, supporting projects that range from understanding the molecular basis of disease to developing new materials and sustainable technologies. The new spectrometer’s enhanced sensitivity will enable investigations of complex biological and engineered systems, including intact cells, protein assemblies, polymers, pharmaceutical formulations, and catalysts.

“This new DNP NMR system will open up avenues of discovery for us not possible with our existing instrumentation,” said Professor Tatyana Polenova, Department of Chemistry and Biochemistry, University of Delaware. “It will impact multiple fields, from structural biology to materials science, and provide training opportunities for students and collaborators. We are grateful for the support of the NSF MRI program, which makes this leap in research capability possible.”

At Northwestern University, the Integrated Molecular Structure Education and Research Center (IMSERC) recently ordered an 800 MHz NMR spectrometer. The instrument will benefit over 15 NIH-funded research groups and the broader Chicago research community, including the Chicago Biomedical Consortium. Key research applications include high-resolution biomolecular NMR for drug discovery, protein-ligand interactions, neurodegenerative disease research, regenerative medicine, and advanced materials development.

“I expect our new 800 MHz NMR spectrometer to transform our ability to conduct high-resolution biomolecular studies and accelerate discoveries in drug development, neurodegenerative disease, and regenerative medicine,” said Dr. Joshua Ziarek, Associate Professor, Department of Pharmacology at the Northwestern University Feinberg School of Medicine. “By making state-of-the-art NMR accessible locally, we are positioning Northwestern as a regional hub for high-field NMR and supporting the next generation of scientific leaders.”

The aggregate value of these three federally funded NMR orders is approximately $10 million, and they are expected to be delivered and installed next year in 2026.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Contacts

Investor Contact:
Joe Kostka

Director – Investor Relations

Bruker Corporation

T: +1 978 313-5800

E: Investor.Relations@bruker.com

Media Contact:
Markus Ziegler

Sr. Director and Head of Group Marketing

Bruker BioSpin

T: +49 172 3733531

E: pr@bruker.com

FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer




FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

– Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase III IMforte study –

– First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to help address the high rate of relapse in ES-SCLC –

– Regimen recommended in National Comprehensive Cancer Network^® Guidelines for SCLC^* –

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq^® (atezolizumab) and Tecentriq Hybreza^® (atezolizumab and hyaluronidase-tqjs) in combination with lurbinectedin (Zepzelca^®) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with Tecentriq or Tecentriq Hybreza, carboplatin and etoposide (CE). This approval marks the first and only combination therapy for the first-line maintenance treatment of ES-SCLC, a highly aggressive disease for which treatment options have been limited. The U.S. National Comprehensive Cancer Network^® Clinical Practice Guidelines in Oncology (NCCN Guidelines^®)* have been updated to include the regimen as a category 2A and preferred option for maintenance treatment of people with ES-SCLC, following induction therapy with Tecentriq and CE.

“For people with extensive-stage small cell lung cancer and their families, the period after induction therapy is often filled with uncertainty, given the high risk of relapse,” said Roy Herbst, M.D., Ph.D., deputy director and chief of medical oncology and hematology at Yale Cancer Center and Smilow Cancer Hospital. “The Tecentriq and Zepzelca combination provides a new option and a proactive approach in this setting shown to improve progression-free and overall survival in patients who haven’t progressed after standard induction treatment with Tecentriq and chemotherapy. The approval may lead to a meaningful shift in how we manage this challenging disease and gives us a new tool to help to delay disease progression and extend survival.”

“The Tecentriq and lurbinectedin combination reduced the risk of disease progression or death by nearly half,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We are proud to deliver this advancement for the small cell lung cancer community in partnership with Jazz Pharmaceuticals, as it reflects our abiding commitment to improving outcomes in the hardest-to-treat cancers.”

The FDA approval is based on results from the Phase III IMforte study, which showed that the Tecentriq and lurbinectedin combination reduced the risk of disease progression or death by 46% and the risk of death by 27%, compared to Tecentriq maintenance therapy alone. Following 3.2 months of induction therapy, the median overall survival for the Tecentriq plus lurbinectedin regimen was 13.2 months versus 10.6 months for Tecentriq alone (stratified hazard ratio [HR]=0.73; 95% CI: 0.57–0.95; p=0.0174). Median progression-free survival by independent assessment was 5.4 months versus 2.1 months, respectively (stratified HR=0.54; 95% CI: 0.43–0.67; p<0.0001). Safety was generally consistent with the known safety profiles of Tecentriq and lurbinectedin.

Today’s approval builds on Tecentriq’s established role in ES-SCLC. In 2019, the FDA approved Tecentriq in combination with chemotherapy for the first-line treatment of adults with ES-SCLC, based on the IMpower133 study, which at the time was the first new treatment option in two decades for this patient population.

*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

About the IMforte study

IMforte [NCT05091567] is a Phase III, open-label, randomized trial evaluating the efficacy and safety of Tecentriq^® (atezolizumab) plus lurbinectedin (Zepzelca^®) versus Tecentriq alone as first-line maintenance therapy for adults (≥18 years) with extensive-stage small-cell lung cancer (ES-SCLC). Patients first received induction therapy with Tecentriq, carboplatin and etoposide for four 21-day cycles. Those without disease progression were then randomized 1:1 to receive maintenance therapy with either Tecentriq plus lurbinectedin or Tecentriq alone until disease progression or unacceptable toxicity. The study enrolled 660 patients in the induction phase and randomized 483 patients in the maintenance phase. The study’s primary endpoints were independent review facility-assessed progression-free survival and overall survival from randomization into the maintenance phase.

The trial is sponsored by Genentech and co-funded by Jazz Pharmaceuticals.

About Tecentriq^® (atezolizumab)

Tecentriq (atezolizumab) is a monoclonal antibody designed to bind with a protein called PD-L1, which is expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.

Important Safety Information and Indications

What are Tecentriq and Tecentriq Hybreza?

Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) are prescription medicines used to treat:

Adults with a type of lung cancer called “extensive stage small cell lung cancer (SCLC)”, which is SCLC that has spread or grown

• Tecentriq or Tecentriq Hybreza may be used with the chemotherapy medicines carboplatin and etoposide as your first treatment
• Tecentriq or Tecentriq Hybreza may be used with the medicine lurbinectedin as maintenance treatment when your lung cancer:
  • has not progressed after first treatment with Tecentriq or Tecentriq Hybreza and the chemotherapy medicines carboplatin and etoposide.

It is not known if Tecentriq Hybreza is safe and effective in children.

It is not known if Tecentriq is safe and effective when used in children for the treatment of SCLC.

What is the most important information about Tecentriq and Tecentriq Hybreza?

Tecentriq and Tecentriq Hybreza can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during your treatment or even after your treatment has ended.

Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:

Lung problems

• cough
• shortness of breath
• chest pain

Intestinal problems

• diarrhea (loose stools) or more frequent bowel movements than usual
• stools that are black, tarry, sticky, or have blood or mucus
• severe stomach-area (abdomen) pain or tenderness

Liver problems

• yellowing of the skin or the whites of the eyes
• severe nausea or vomiting
• pain on the right side of their stomach area (abdomen)
• dark urine (tea colored)
• bleeding or bruising more easily than normal

Hormone gland problems

• headaches that will not go away or unusual headaches
• eye sensitivity to light
• eye problems
• rapid heartbeat
• increased sweating
• extreme tiredness
• weight gain or weight loss
• feeling more hungry or thirsty than usual
• urinating more often than usual
• hair loss
• feeling cold
• constipation
• your voice gets deeper
• dizziness or fainting
• changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness

Kidney problems

• decrease in your amount of urine
• blood in your urine
• swelling of your ankles
• loss of appetite

Skin problems

• rash
• itching
• skin blistering or peeling
• painful sores or ulcers in mouth or nose, throat, or genital area
• fever or flu-like symptoms
• swollen lymph nodes

Problems can also happen in other organs.

These are not all of the signs and symptoms of immune system problems that can happen with Tecentriq or Tecentriq Hybreza. Call or see your healthcare provider right away for any new or worse signs or symptoms, including:

• Chest pain, irregular heartbeat, shortness of breath, or swelling of ankles
• Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs
• Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight
• Persistent or severe muscle pain or weakness, muscle cramps
• Low red blood cells, bruising

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include:

• chills or shaking
• itching or rash
• flushing
• shortness of breath or wheezing
• dizziness
• feeling like passing out
• fever
• back or neck pain

Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with Tecentriq or Tecentriq Hybreza. Your healthcare provider will monitor you for these complications.

Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with Tecentriq or Tecentriq Hybreza. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with Tecentriq or Tecentriq Hybreza if you have severe side effects.

Before you receive Tecentriq or Tecentriq Hybreza, tell your healthcare provider about all of your medical conditions, including if you:

• have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus
• have received an organ transplant
• have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
• have received radiation treatment to your chest area
• have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
• are pregnant or plan to become pregnant. Tecentriq and Tecentriq Hybreza can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Tecentriq or Tecentriq Hybreza. Females who are able to become pregnant:
  • Your healthcare provider should do a pregnancy test before you start treatment with Tecentriq or Tecentriq Hybreza.
  • You should use an effective method of birth control during your treatment and for at least 5 months after the last dose of Tecentriq or Tecentriq Hybreza.
• are breastfeeding or plan to breastfeed. It is not known if Tecentriq or Tecentriq Hybreza passes into your breast milk. Do not breastfeed during treatment and for at least 5 months after the last dose of Tecentriq or Tecentriq Hybreza.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of Tecentriq when used alone include:

• feeling tired or weak
• decreased appetite
• nausea
• cough
• shortness of breath

The most common side effects of Tecentriq Hybreza when used alone include:

• feeling tired or weak
• muscle or bone pain
• cough
• shortness of breath
• decreased appetite

The most common side effects of Tecentriq and Tecentriq Hybreza when used in lung cancer with other anti-cancer medicines include:

• feeling tired or weak
• nausea
• hair loss
• constipation
• diarrhea
• decreased appetite

Tecentriq and Tecentriq Hybreza may cause fertility problems in females, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of Tecentriq and Tecentriq Hybreza. Ask your healthcare provider or pharmacist for more information about the benefits and side effects of Tecentriq and Tecentriq Hybreza.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Prescribing Information for Tecentriq and Tecentriq Hybreza and the Medication Guides for Tecentriq and Tecentriq Hybreza for additional Important Safety Information.

About Genentech in cancer immunotherapy

To learn more about Genentech’s scientific-led approach to cancer immunotherapy, please follow this link: https://www.gene.com/cancer-immunotherapy.

About Genentech

Founded nearly 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

ZEPZELCA is a trademark of Pharma Mar, S.A. used by Jazz Pharmaceuticals under license.

All trademarks used or mentioned in this release are protected by law.

Contacts

Media Contact: Andrea Wallace (650) 467-6800

Advocacy Contact: Katie Creme Henry (202) 258-8228

Investor Contacts: Loren Kalm (650) 225-3217

Bruno Eschli +41 616875284

Pharmanovia Appoints Stephan Eder as Chief Executive Officer




Pharmanovia Appoints Stephan Eder as Chief Executive Officer

BASILDON, England–(BUSINESS WIRE)–Pharmanovia today announced the appointment of Stephan Eder as Chief Executive Officer (CEO) of Pharmanovia, effective today.

Stephan is a highly experienced leader, with over two decades leading teams and businesses in senior roles in multi-national pharma. Most recently, he served on the Executive Committee at Stada, a private equity backed company focusing on Generics, Specialty and Consumer Healthcare, in several commercial roles, most importantly as Head of Europe, leading a business with sales of EUR 3.5bn and over 6,000 employees. Prior to that, Stephan worked at Novartis and latterly moved over to Sandoz and Hexal, where he held a number of senior positions including CEO, Hexal/Sandoz Germany.

Guido Oelkers, Chair of Pharmanovia, commented: “Stephan has a strong track record delivering sustainable growth across diverse businesses. He has demonstrated a high degree of ambition and urgency and is passionate about building strong teams.

“The board welcomes Stephan as the incoming CEO and looks forward to the company’s future development under his leadership.”

Stephan Eder added, “I am excited to join an organisation that not only owns trusted established brands but is poised to launch some exciting innovative medicines in the next couple of years. I am impressed by the team and see a very strong commitment to making a difference to patient’s lives. This sense of purpose coupled with the ongoing support from our shareholders, gives me conviction to lead the company to the next phase of growth.”

Notes to editors

About Pharmanovia

Pharmanovia is a global healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.

We do this by rediscovering, repurposing or re-engineering established medicines to improve patient outcomes and experiences as well as identifying new chemical entities that complement our existing portfolio to address unmet need.

With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.

For more information about Pharmanovia, please visit www.pharmanovia.com.

Contacts

For further information, please contact:

Alison Dyson, Director of Communications, Pharmanovia

07912887250/ communications@pharmanovia.com

LEO Pharma Closes Deal for Spevigo®




LEO Pharma Closes Deal for Spevigo®

• Adding Spevigo^® is a significant step forward in LEO Pharma’s focused growth strategy, to accelerate and expand patients’ access to treatments for medical dermatological conditions, including generalized pustular psoriasis (GPP), a rare and severe skin condition
• Spevigo® (spesolimab) is a first-in-class IL-36R antagonist successfully developed and launched by Boehringer Ingelheim and approved globally for the treatment and prevention of GPP flares
• Spesolimab is also being investigated for the treatment of other IL-36-mediated skin diseases

BALLERUP, Denmark–(BUSINESS WIRE)–GLOBAL RELEASE – NOT INTENDED FOR UK MEDIA

LEO Pharma, a global leader in medical dermatology, has successfully closed the deal for Spevigo® with Boehringer Ingelheim, as announced on July 14, 2025, following approval from all relevant authorities. The terms of the transaction and the financial assumptions outlined in LEO Pharma’s initial press release regarding the deal remain unchanged. LEO Pharma and Boehringer Ingelheim will continue working closely together on finalizing all aspects of the transition of Spevigo® to LEO Pharma.

Spevigo® is an innovative, humanized, and selective monoclonal antibody that targets and blocks the activation of the interleukin-36 (IL-36) receptor – a key signalling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases, including generalized pustular psoriasis (GPP).¹²³

Spevigo® will join LEO Pharma’s global dermatology portfolio as its third strategic brand. Spevigo^® is available in more than 40 countries including the U.S., Japan, China, and most European countries to treat GPP flares in adults.⁴

“With our specialization in dermatology, LEO Pharma is uniquely positioned to take over Spevigo® and expand access to care, bringing progress to underserved patients,” said Christophe Bourdon, CEO of LEO Pharma. “We are committed to ensuring this innovative treatment reaches its full potential by building on Boehringer Ingelheim’s pioneering efforts. Bringing Spevigo® to more patients is an important step in helping those living with GPP, a community with limited treatment options.”

GPP is a rare, heterogeneous, and potentially life-threatening skin disease. It is characterized by the accumulation of neutrophils (a type of white blood cell) in the skin, leading to painful, sterile pustules across the body. The disease course varies, with some patients experiencing relapsing episodes with recurrent flares – often accompanied by fever, malaise, fatigue, and a risk of organ failure – while others endure persistent disease with intermittent flares. ^7891011

LEO Pharma will be responsible for commercialization and further development of Spevigo®, leveraging its global commercial platform in medical dermatology to accelerate and expand access to treatment for patients with GPP. Spesolimab is also being investigated for the treatment of other IL-36-mediated skin diseases, including pyoderma gangrenosum.

Spevigo® will be included in the financials for FY 2025 with three months of impact. Preliminary assessment suggests that Spevigo® will contribute less than one percent to revenue growth in 2025. Ongoing costs for Spevigo®, mainly related to development activities, are preliminarily assessed to reduce the adjusted EBITDA margin in 2025 by up to two percentage points. Excluding Spevigo® the outlook for revenue growth of 7-9% at constant exchange rates and an adjusted EBITDA margin of 16-18%, as communicated with the H1 2025 Interim Report, published August 18, 2025, is unchanged.

— LEO Pharma A/S —

About Spevigo®

Spevigo® is a humanized, selective antibody that specifically blocks the activation of the IL-36R, a signalling pathway within the immune system shown to be involved in the pathogenesis of several autoinflammatory diseases, including GPP. It is the first targeted therapy for the treatment of GPP and has been evaluated in the largest clinical program specifically for the treatment of patients with GPP.¹²³

About generalized pustular psoriasis (GPP)

GPP is a chronic, heterogenous, neutrophilic inflammatory disease associated with skin and systemic symptoms that is distinct from plaque psoriasis. GPP is recognized as a separate clinical entity from other forms of psoriasis, with the IL-36 pathway being a key driver of GPP and triggering response to treatment.⁵⁶ GPP can become life-threatening (mortality rates ranging from 2% to 16%) due to severe complications, such as multisystem organ failure and sepsis requiring urgent hospital care; many GPP patients also suffer from various comorbidities, which contribute to the ongoing burden for the patient and healthcare systems.⁸⁷ GPP symptoms appear unpredictable and present on a continuum, which greatly impacts a patient’s quality of life, and may cause fear and anxiety over the disease course, as well as long-term impacts on quality of life related to work/school, emotional health, social activities, and finances.⁸⁸⁹

About LEO Pharma

LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com.

¹ Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402:1541–1551.

² Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11:e043666.

³ Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385:2431–2440.

⁴ Record on file.

⁵ Marrakchi S, Puig L. Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:13–19.

⁶ Prinz JC, Choon SE, Griffiths CEM, et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review. J Eur Acad Dermatol Venereol. 2023;37:256–273.

⁷ Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:21–29.

⁸ Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15:907–919.

⁹ Reisner DV, Johnsson FD, Kotowsky N, et al. Impact of generalized pustular psoriasis from the perspective of people living with the condition: Results of an online survey. Am J Clin Dermatol. 2022;23:65–71.

Contacts

Investors

Christian Sørup Ryom, Investor Relations

E-mail: chsoe@leo-pharma.com
Phone: +45 3089 9083

Media

Jeppe Ilkjær, Global Communications

E-mail: jeilk@leo-pharma.com
Phone: +45 3050 2014

Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares




Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares

Offering was led by an initial investment from a premier healthcare-dedicated investor alongside multiple large existing shareholders

Company’s total cash position expected to be approximately $70 million following closing

VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)–Alpha Cognition Inc. (Nasdaq: ACOG) (the “Company”), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced the pricing of its oversubscribed underwritten public offering of 5,600,000 common shares (or pre-funded warrants in lieu thereof), at a public offering price of $6.25 per share. The gross proceeds of the offering are approximately $35.0 million, before deducting underwriting discounts, commissions, and estimated offering expenses. All securities in this offering were sold by the Company.

The Company plans to allocate the net proceeds for the acceleration of commercial launch, with an emphasis on sales expansion, marketing investment, enhancing payer coverage, and reimbursement infrastructure. These investments are designed to maximize near-term adoption while laying the foundation for long-term revenue growth and a sustainable commercial presence in the Alzheimer’s treatment landscape.

“The enthusiastic support from both existing and new healthcare investors underscores confidence in our vision and growth potential,” said Michael McFadden, Chief Executive Officer. “We believe the net proceeds from this offering will accelerate the commercialization of ZUNVEYL® (Benzgalantamine), enabling us to capitalize on early commercial learnings and set the foundation for key initiatives that will drive long-term shareholder value.”

The Company has granted the underwriter a 30-day option to purchase up to an additional 840,000 common shares to cover over-allotments, if any, at the per share public offering price, less underwriting discounts and commissions.

Titan Partners Group, a division of American Capital Partners, is acting as sole bookrunner for the offering.

The offering is expected to close on or about October 2, 2025, subject to the satisfaction of customary closing conditions.

The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-289792) filed with the Securities and Exchange Commission (“SEC”) on August 22, 2025, and declared effective by the SEC on August 29, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available for free on the SEC’s website at www.sec.gov. A final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at prospectus@titanpartnersgrp.com.

Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s Disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.

ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.

Forward-looking Statements

This news release includes forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the completion and timing of the Company’s public offering, the satisfaction of customary closing conditions, the gross proceeds the Company expects to receive and the intended use of proceeds therefrom. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company’s filings with the SEC, including those risk factors under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 31, 2025 and our periodic reports on Form 10-Q and Form 8-K filed with the SEC available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.

Contacts

For further information:

Investor Relations

IR@alphacognition.com
https://www.alphacognition.com/

Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock




Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are being offered by Enanta. The offering is expected to close on October 2, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds to Enanta from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $65.0 million. In addition, Enanta has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

J.P. Morgan, Jefferies and Evercore ISI are acting as joint book-running managers for the offering.

The offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed with the Securities and Exchange Commission (the SEC) on November 22, 2023 and became effective on February 8, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available for free on the SEC’s website located at http://www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations.

Forward Looking Statements

Statements contained in this press release regarding Enanta’s expectations regarding the gross proceeds from the offering and the closing of the offering are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated closing date of the offering. These forward-looking statements are based upon Enanta’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, Enanta’s expectations regarding the completion of the offering, as well as those risks more fully discussed in the section entitled “Risk Factors” in Enanta’s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 and in Enanta’s subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Enanta undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contacts

Media and Investors Contact:
Jennifer Viera

jviera@enanta.com